Lipum AB is a Swedish clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic inflammatory diseases. The company’s lead drug candidate, SOL-116, is a humanized monoclonal antibody that targets Bile Salt-Stimulated Lipase (BSSL), a previously overlooked molecule involved in inflammatory processes. Following successful Phase I clinical development, Lipum is advancing SOL-116 as a potential new treatment for rheumatoid arthritis and other inflammatory conditions with significant unmet medical needs. Based in Umeå, Sweden, Lipum combines academic excellence with industry expertise to bring first-in-class therapies to patients.

Visit Lipum »

Age Labs AS is a Norwegian life science company specializing in the discovery and development of biomarkers for the early detection of age-related diseases. The company applies advanced epigenetics, machine learning, and predictive analytics to identify disease-related biological signals and improve patient stratification. Age Labs has developed a strong expertise in biomarker discovery for inflammatory diseases, including rheumatoid arthritis, and collaborates with leading healthcare institutions, biobanks, and industry partners across Europe.

Visit Age Labs »

MERAccess AB is a specialized life science consultancy focused on improving patient access to innovative medicines. The company provides expertise in market access, value demonstration, health economics, reimbursement strategies, and stakeholder engagement. Through close collaboration with healthcare providers, industry partners, and decision-makers, MERAccess supports the translation of scientific innovation into accessible healthcare solutions that benefit patients and healthcare systems alike.

Visit MERAccess »

The Centre for Human Drug Research (CHDR) is an independent, non-profit research institute and leading early-phase clinical research organization based in Leiden, the Netherlands. CHDR specializes in first-in-human and Phase I clinical studies and is internationally recognized for its expertise in clinical pharmacology, biomarker development, and innovative research methodologies. By combining scientific excellence with state-of-the-art facilities, CHDR accelerates the development of new therapies and contributes to more efficient and effective drug development.

Visit CHDR »